ArticleCureus2026
Prognostic Value of Lymph-Node Micrometastases and Isolated Tumour Cells in Gastric Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Lymph node status is a crucial prognostic determinant in gastric cancer (GC). Conventional haematoxylin-eosin (H&E) assessment overlooks the micro volume of nodal disease. This study explored the prevalence and prognostic significance of lymph-node micrometastases (Mic) and isolated tumour cells (ITC) detected by cytokeratin AE1/AE3 immunohistochemistry (IHC) in patients undergoing gastrectomy with curative intent. Methods A retrospective, single-centre analysis of patients with gastric adenocarcinoma treated between 2014 and 2019 by curative intent gastrectomy with D2 lymphadenectomy and with IHC assessment of lymph nodes (LN). Nodal involvement was classified as macrometastases (>2 mm), Mic (>0.2-2 mm), or ITC (≤0.2 mm). Clinicopathological characteristics and survival outcomes were obtained from the institutional database. Data were analysed using χ²/Fisher's exact and Wilcoxon tests. Overall survival (OS) was analysed using Kaplan-Meier curves and log-rank tests. Results Eighty-six patients were included (mean age 67.2±11.2 years). A total of 1,974 lymph nodes were examined (mean 22.95±7.43 per patient): 256 (12.97%) contained macrometastases, 21 (1.06%) Mic and 31 (1.57%) ITC. Sixteen patients (18.6%) had Mic and/or ITC (ITC+/Mic+). Tumours larger than 20 mm with lymphovascular invasion were significantly associated with the presence of ITC+/Mic+. In node-negative (pN0) patients, IHC uncovered occult nodal disease in six cases (13.6%). In the overall cohort, five-year OS was 55.8%, and the presence of ITC+/Mic+ did not significantly affect OS across tumour, nodes, metastases (TNM) and pathological lymph node (pN) categories. In the subgroup treated with perioperative chemotherapy, the presence of ITC+/Mic+ was associated with a lower five-year OS (p=0.023). OS was comparable between pN0 patients with ITC+/Mic+ and those with node-positive (pN1) disease (p=0.624). Conclusion Micrometastases and ITC are detected in a relevant proportion of gastric cancer patients and are associated with adverse pathological features, but they did not independently influence OS in this clinical cohort. Their prognostic impact might be relevant in patients receiving perioperative chemotherapy. Routine IHC assessment is not sustained by these data and may be better suited for selected high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.